Fund moves
2.3%Stake
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
EVMN · NYSE · Pharmaceutical Preparations
Evommune (EVMN) · oqro.io/stocks/EVMN · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Evommune is on record in SEC filings since 2006.
No open-market sale by an insider of Evommune (EVMN) was filed with the SEC in the last 90 days.
No trade in Evommune (EVMN) was disclosed by a member of Congress in the last 12 months.
Evommune's next results are expected on Mar 3, 2027. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$7.04−0.20 (−2.76%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−62.4% (−$11.67) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $18.71 on Nov 20, 2025 to $7.04 on Nov 20, 2026 (−62.4%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 5 13F position changes for 2 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Palo Alto, Ca.
Last 12 months
−62.4%
Market value
$284M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 3.39M shares sold short (8.4% of shares outstanding), −4.1% vs the previous count, 3.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$13M
+85.7% vs the year before
Net income, fiscal 2025
−$68.9M
A loss for the year
Shares outstanding
41.3M
As of Nov 10, 2026
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
A Schedule 13D means the holder owns more than 5% and keeps the option to push for changes: board seats, a sale, buybacks. It must be filed within 5 business days.
Fund moves
3 tracked managers disclosed the same change for Q1 2026. From a 13F filed May 15, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
3 tracked managers disclosed the same change for Q1 2026. From a 13F filed May 15, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
3 tracked managers disclosed the same change for Q1 2026. From a 13F filed May 15, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
On the public record for Evommune over the 12 months to Nov 20, 2026: 1 clinical trial.
RA Capital Management, L.P.
13D · may seek influence · Amended · 3.49M shares · filed Nov 10, 2026
Point72 Asset Management, L.P.
13G · passive · Amended · 2.43M shares · filed Nov 16, 2026
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 7,000 words.
Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. Our mission is to improve patients’ daily lives and prevent the long-term effects of uncontrolled inflammation that are a consequence of the limitations of existing therapies. To achieve this, we are advancing a portfolio of differentiated product candidates that target key drivers of chronic inflammation.
And 16 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 5, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
0 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in migraine. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Revenue
$0
−100.0% vs the same quarter a year earlier
Free cash flow, last 12 months
−$91M
This quarter −$26.1M, a year earlier −$9.77M
Net debt
—
Debt —, cash $47.6M, at Sep 30, 2026
Net income, last 12 months
−$113M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 12, 2026.
Last results
Nov 12, 2026
Within the 30 days after it, until Dec 12, 2026
Next results, expected
Mar 3, 2027
Purchases after results
Not enough history
From Evommune's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Evommune's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Off-exchange trading: 40.2% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (26.7% on ATS, 13.5% with other brokers), below its 26-week average of 44.9%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (13.7%), SIGMA X2 (9.8%), INTELLIGENT CROSS LLC (8.6%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Latest annual report filed Mar 5, 2026. Read the filing
75 risk factor headings in this report. There is no earlier annual report to compare it with.
From time to time, we may become involved in or be subject to legal proceedings, claims and litigation arising from the ordinary course of business. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors
Source: SEC EDGAR, Form 10-K filed Mar 5, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.